Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Set to Expand Significantly in Terms of Value and CAGR by 2029

 Use Code ONLINE20 to Save 20% On Global Market Reports — Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

 

 What Is the Growth Potential of the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Size Over 2025–2034?
 The next-generation sequencing (NGS)-based molecular diagnostics market size has grown strongly in recent years. It will grow from $2.10 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing demand for personalized medicine, increasing adoption of next-generation sequencing in clinical settings, increasing awareness among clinicians and patients, increasing availability of cost-effective next-generation sequencing platforms, and increasing applications in non-invasive prenatal testing.
 
 The next-generation sequencing (NGS)-based molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.01 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising demand for decentralized diagnostic solutions, rising use of artificial intelligence in next-generation sequencing data interpretation, rising burden of antibiotic resistance, growing regulatory support for next-generation sequencing-based tests, and growing use of next-generation sequencing in pharmacogenomics. Major trends in the forecast period include technology advancements in sequencing accuracy, technology-driven automation in sample preparation, integration with pharmaceutical development pipelines, integration of next-generation sequencing in public health surveillance, and developing disease-specific next-generation sequencing panels.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28281&type=smp
 
 What Are the Leading Drivers Behind the Growth of the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
 The increasing incidence of infectious diseases is expected to propel the growth of the next-generation sequencing (NGS)-based molecular diagnostics market going forward. Infectious diseases are disorders caused by microorganisms such as bacteria, viruses, fungi, or parasites that invade the body, multiply, and disrupt normal body functions. The prevalence of infectious diseases is increasing as rising travel and migration accelerate the transmission of pathogens across regions and borders. Next-generation sequencing (NGS)-based molecular diagnostics helps detect infectious diseases by providing comprehensive and precise analysis of pathogens. It reduces diagnostic time by simultaneously identifying multiple microorganisms, improving treatment accuracy and patient care. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government agency, tuberculosis (a contagious bacterial infection that primarily affects the lungs) cases in England rose to 4,850 in 2023, an increase of 10.7% from 4,380 cases in 2022. Therefore, the increasing incidence of infectious diseases is driving the growth of the next-generation sequencing (NGS)-based molecular diagnostics market.
 
 Which Market Segment Offers the Most Significant Growth Opportunities in the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
 The next-generation sequencing (NGS)-based molecular diagnostics market covered in this report is segmented as
 
 1) By Type: Instruments, Reagents And Consumables, Software And Services, Panels And Assays, Sample Preparation Kits
 2) By Application: Microbiology, Infectious Diseases, Oncology, Genetic Tests, Other Applications
 3) By End User: Research Centers And Academics, Hospitals And Clinical Laboratories, Other End Users
 
 Subsegments:
 1) By Instruments: Benchtop Sequencers, High-Throughput Sequencers, Portable Or Handheld Sequencers, Clinical Or Diagnostic Sequencers, Automated Library Preparation Systems, Data Analysis And Bioinformatics Hardware
 2) By Reagents And Consumables: Sequencing Reagents And Kits, Library Preparation Reagents, Target Enrichment Reagents, Amplification Reagents, Sequencing Flow Cells And Chips, Deoxyribonucleic Acid (DNA) Or Ribonucleic Acid (RNA) Extraction Reagents, Quality Control Reagents
 3) By Software And Services: Data Analysis Software, Bioinformatics Pipelines, Cloud-Based Genomic Platforms, Clinical Interpretation Tools, Data Storage And Management Services, Custom Bioinformatics Services, Genomic Database Services
 4) By Panels And Assays: Oncology Panels, Infectious Disease Panels, Carrier Screening Panels, Reproductive Health Panels, Rare Disease Or Genetic Disorder Panels, Pharmacogenomics Panels, Whole-Exome Or Whole-Genome Assays
 5) By Sample Preparation Kits: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Library Preparation Kits, Target Enrichment Kits, Amplification And Cleanup Kits, Single-Cell Preparation Kits, Low-Input Or Degraded Sample Kits
 
 Which Future-Ready Trends Are Expected to Influence the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
 Major companies operating in the next-generation sequencing (NGS)-based molecular diagnostics market are focusing on developing technologically advanced products, such as next-generation sequencing (NGS)-based panels, to enhance the accuracy, accessibility, and efficiency of genetic testing. Next-generation sequencing (NGS)-based panels are targeted sets of genes or genomic regions analyzed simultaneously using NGS technology to detect specific hereditary or somatic mutations for faster and more precise molecular diagnostics. For instance, in May 2022, Genes2Me Pvt. Ltd., an India-based medical equipment manufacturer, launched a comprehensive range of next-generation sequencing (NGS)-based panels designed for oncology, personalized medicine, and hereditary disease diagnostics. These panels cover clinically significant genes with high sensitivity and comprehensive variant detection, including single-nucleotide variations, insertions or deletions, copy number variations, microsatellite instability, fusions, and oncogenic viruses, while also measuring tumor mutation burden. The Genes2Me PAN cancer panel covers around 525 genes, requiring just 50 ng of nucleic acid, and offers streamlined workflows compatible with major NGS platforms.
 
 Who Are the Top Industry Players Driving the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Growth?
 Major companies operating in the next-generation sequencing (ngs)-based molecular diagnostics market are Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., and TATAA Biocenter AB.
 
 Get the detailed next-generation sequencing (ngs)-based molecular diagnostics market report today
 https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-ngs-based-molecular-diagnostics-global-market-report
 
 Which Regional Markets Offer the Most Promising Growth Opportunities for the Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
 North America was the largest region in the next-generation sequencing (NGS)-based molecular diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in next-generation sequencing (NGS)-based molecular diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company